

Jorge J Nieva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7949679/publications.pdf>

Version: 2024-02-01

144
papers

6,551
citations

94433

37
h-index

64796

79
g-index

147
all docs

147
docs citations

147
times ranked

8610
citing authors

#	ARTICLE	IF	CITATIONS
1	Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1&2 trials. <i>Lancet Oncology</i> , The, 2020, 21, 271-282.	10.7	1,034
2	AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP. <i>New England Journal of Medicine</i> , 2006, 355, 1672-1681.	27.0	489
3	Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. <i>Nature</i> , 2011, 477, 99-102.	27.8	459
4	Evidence for Antibody-Catalyzed Ozone Formation in Bacterial Killing and Inflammation. <i>Science</i> , 2002, 298, 2195-2199.	12.6	330
5	Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α -synuclein fibrilization. <i>Nature Chemical Biology</i> , 2006, 2, 249-253.	8.0	312
6	Evidence for Ozone Formation in Human Atherosclerotic Arteries. <i>Science</i> , 2003, 302, 1053-1056.	12.6	263
7	Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. <i>Physical Biology</i> , 2012, 9, 016003.	1.8	252
8	Metabolite-initiated protein misfolding may trigger Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4752-4757.	7.1	204
9	Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. <i>Physical Biology</i> , 2012, 9, 016001.	1.8	176
10	High speed detection of circulating tumor cells. <i>Biosensors and Bioelectronics</i> , 2006, 21, 1893-1899.	10.1	167
11	Detection of NRG1 Gene Fusions in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4966-4972.	7.0	145
12	Case study of the morphologic variation of circulating tumor cells. <i>Human Pathology</i> , 2007, 38, 514-519.	2.0	144
13	Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. <i>Blood</i> , 2003, 102, 810-813.	1.4	143
14	Tuberculosis following PD-1 blockade for cancer immunotherapy. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	141
15	Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1901-1911.	1.1	127
16	Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. <i>Physical Biology</i> , 2012, 9, 016005.	1.8	120
17	Cytomorphology of Circulating Colorectal Tumor Cells: A Small Case Series. <i>Journal of Oncology</i> , 2010, 2010, 1-7.	1.3	108
18	High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. <i>Physical Biology</i> , 2012, 9, 016004.	1.8	96

#	ARTICLE	IF	CITATIONS
19	Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. <i>Thrombosis Research</i> , 2008, 122, 604-609.	1.7	93
20	Spreaders and Sponges Define Metastasis in Lung Cancer: A Markov Chain Monte Carlo Mathematical Model. <i>Cancer Research</i> , 2013, 73, 2760-2769.	0.9	82
21	A Stochastic Markov Chain Model to Describe Lung Cancer Growth and Metastasis. <i>PLoS ONE</i> , 2012, 7, e34637.	2.5	72
22	Circulating Tumor Cells From Well-Differentiated Lung Adenocarcinoma Retain Cytomorphologic Features of Primary Tumor Type. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 1468-1471.	2.5	71
23	Characterization of KRAS Mutation Subtypes in Non-“small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2577-2584.	4.1	66
24	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1139-1145.	2.5	63
25	The antibody-catalyzed water oxidation pathway “a new chemical arm to immune defense?. <i>Trends in Biochemical Sciences</i> , 2004, 29, 274-278.	7.5	61
26	Circulating Tumor Microemboli Diagnostics for Patients with Non-“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1111-1119.	1.1	61
27	Injuries in Youth Ice Hockey: A Pilot Surveillance Strategy. <i>Mayo Clinic Proceedings</i> , 1995, 70, 350-356.	3.0	59
28	Radiomics in Pulmonary Lesion Imaging. <i>American Journal of Roentgenology</i> , 2019, 212, 497-504.	2.2	59
29	ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. <i>Lung Cancer</i> , 2012, 77, 421-426.	2.0	56
30	A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 376-382.	1.5	50
31	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. <i>Cancer</i> , 2013, 119, 2383-2390.	4.1	45
32	Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 294.	4.4	45
33	Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 1468-71.	2.5	41
34	Proatherogenic Effects of the Cholesterol Ozonolysis Products, Atheronal-A and Atheronal-B. <i>Biochemistry</i> , 2006, 45, 7162-7170.	2.5	40
35	Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding. <i>Scientific Reports</i> , 2019, 9, 3214.	3.3	40
36	Lipid-Derived Aldehydes Accelerate Light Chain Amyloid and Amorphous Aggregation. <i>Biochemistry</i> , 2008, 47, 7695-7705.	2.5	39

#	ARTICLE	IF	CITATIONS
37	Cholesterol Secosterol Aldehydes Induce Amyloidogenesis and Dysfunction of Wild-Type Tumor Protein p53. <i>Chemistry and Biology</i> , 2011, 18, 920-927.	6.0	38
38	Spatiotemporal progression of metastatic breast cancer: a Markov chain model highlighting the role of early metastatic sites. <i>Npj Breast Cancer</i> , 2015, 1, 15018.	5.2	37
39	Effect of Blood Collection Tube Type and Time to Processing on the Enumeration and High-Content Characterization of Circulating Tumor Cells Using the High-Definition Single-Cell Assay. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 198-207.	2.5	36
40	A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 110-119.	1.1	36
41	A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 1163-1164e.	3.7	32
42	An Observational Study of Circulating Tumor Cells and 18F-FDG PET Uptake in Patients with Treatment-Naive Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67733.	2.5	32
43	The ratio of cholesterol 5,6-secosterols formed from ozone and singlet oxygen offers insight into the oxidation of cholesterol in vivo. <i>Chemical Communications</i> , 2009, , 3098.	4.1	29
44	Entropy, complexity and Markov diagrams for random walk cancer models. <i>Scientific Reports</i> , 2014, 4, 7558.	3.3	28
45	Adrenal Metastases in Lung Cancer: Clinical Implications of a Mathematical Model. <i>Journal of Thoracic Oncology</i> , 2014, 9, 442-446.	1.1	23
46	Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005819.	1.2	23
47	SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. <i>British Journal of Haematology</i> , 2005, 129, 791-794.	2.5	22
48	Fluid biopsy for solid tumors: a patient's companion for lifelong characterization of their disease. <i>Future Oncology</i> , 2012, 8, 989-998.	2.4	22
49	Patient reported outcomes can improve performance status assessment: a pilot study. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 41.	1.9	22
50	A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs. <i>Frontiers in Oncology</i> , 2020, 10, 591.	2.8	22
51	Immunoglobulins can utilize riboflavin (Vitamin B2) to activate the antibody-catalyzed water oxidation pathway. <i>Immunology Letters</i> , 2006, 103, 33-38.	2.5	20
52	Oncolytic viruses: perspectives on clinical development. <i>Current Opinion in Virology</i> , 2015, 13, 55-60.	5.4	19
53	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. <i>British Journal of Cancer</i> , 2022, 126, 514-520.	6.4	19
54	Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 319-337.	2.8	19

#	ARTICLE	IF	CITATIONS
55	A new anion exchange purification method for Cu stable isotopes in blood samples. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 765-776.	3.7	18
56	A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites. <i>Oncology</i> , 2012, 82, 315-320.	1.9	17
57	Biophysical technologies for understanding circulating tumor cell biology and metastasis. <i>Translational Lung Cancer Research</i> , 2017, 6, 473-485.	2.8	13
58	Intravenous 5-fluoro-2â€²-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 979-993.	2.3	13
59	Long-Term Dosing of AMG 531 Is Effective and Well Tolerated in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2005, 106, 220-220.	1.4	13
60	A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D). <i>European Journal of Cancer</i> , 2016, 69, S11.	2.8	11
61	Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 839-853.	2.1	11
62	3640 Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases. <i>Annals of Oncology</i> , 2020, 31, S397-S398.	1.2	10
63	Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9110-9110.	1.6	10
64	Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. <i>Oncotarget</i> , 2019, 10, 7016-7030.	1.8	10
65	Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer. <i>Cancers</i> , 2022, 14, 758.	3.7	10
66	Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. <i>Oral Oncology</i> , 2020, 111, 104928.	1.5	9
67	Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGENTM): Early Clinical Results. <i>Cancers</i> , 2021, 13, 4104.	3.7	9
68	Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2627-2627.	1.6	9
69	Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Nonâ€™Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020, 32, 153-159.	0.6	8
70	DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9100-9100.	1.6	8
71	Purification and characterization of sideroblasts from patients with acquired and hereditary sideroblastic anaemia. <i>British Journal of Haematology</i> , 2008, 143, 446-450.	2.5	7
72	Measurement of Blood-Borne Tissue Factor Procoagulant Activity in Healthy Individuals and Cancer Patients Using a Novel Assay.. <i>Blood</i> , 2005, 106, 1938-1938.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Use of optophoresis as an in vitro predictor of cell response to chemotherapy for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 2194-2202.	1.3	6
74	First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2502-2502.	1.6	6
75	Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8535-8535.	1.6	6
76	MA 07.02 Response to Ensartinib in TKI Na ⁺ -ve ALK+ NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1826.	1.1	5
77	Development of metastatic brain disease involves progression through lung metastases in <i>EGFR</i> mutated non-small cell lung cancer. <i>Convergent Science Physical Oncology</i> , 2017, 3, 035002.	2.6	5
78	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. <i>Clinical Biomechanics</i> , 2018, 56, 61-69.	1.2	5
79	Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 968.	2.8	5
80	A randomized double-blind phase II study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: Alliance (NCCTG) N0923 study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7509-7509.	1.6	5
81	A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2648-TPS2648.	1.6	5
82	Characterization of NRG1 gene fusion events in solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3113-3113.	1.6	5
83	Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. <i>Oncotarget</i> , 2021, 12, 2449-2458.	1.8	5
84	Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 583-601.	2.1	4
85	The clinical significance of circulating tissue factor in prostate cancer. <i>Thrombosis and Haemostasis</i> , 2007, 97, 329-330.	3.4	4
86	Incidence of <i>Neuregulin1</i> (<i>NRG1</i>) gene fusions across tumor types.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12084-12084.	1.6	4
87	Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data. <i>Drugs - Real World Outcomes</i> , 2022, 9, 333-345.	1.6	4
88	Mining Human Mobility to Quantify Performance Status. , 2017, , .		3
89	P1.01-105 US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attrition Data from First-To-Second-Line Treatment. <i>Journal of Thoracic Oncology</i> , 2019, 14, S402.	1.1	3
90	Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2021, 160, 92-98.	2.0	3

#	ARTICLE	IF	CITATIONS
91	Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2013, 31, 6047-6047.	1.6	3
92	A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, TPS9110-TPS9110.	1.6	3
93	Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9544-9544.	1.6	3
94	Development of metastatic brain disease involves progression through lung metastases in mutated non-small cell lung cancer. Convergent Science Physical Oncology, 2017, 3, .	2.6	3
95	A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).. Annals of Oncology, 2016, 27, vi452.	1.2	2
96	P2.13-10 Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC. Journal of Thoracic Oncology, 2018, 13, S801-S802.	1.1	2
97	Effect of prior therapy on tumor mutational burden in NSCLC. Translational Lung Cancer Research, 2021, 10, 1231-1238.	2.8	2
98	<i>STK11</i> / <i>TP53</i> co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.. Journal of Clinical Oncology, 2021, 39, 9087-9087.	1.6	2
99	Phase II trial of soluble EphB4-albumin in combination with PD-1 antibody (pembrolizumab) in relapsed/refractory head neck squamous cell carcinoma.. Journal of Clinical Oncology, 2021, 39, 6016-6016.	1.6	2
100	Significant Activity of Dasatinib in CLL Demonstrated by Ex-Vivo Assay.. Blood, 2007, 110, 4197-4197.	1.4	2
101	Performance of the high-definition circulating tumor cells (HD-CTC) assay in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, e21074-e21074.	1.6	2
102	The effects of multidisciplinary clinics on the variability in timeliness of care for lung cancer patients.. Journal of Clinical Oncology, 2013, 31, e17533-e17533.	1.6	2
103	Serum phosphatidylcholine is lower among breast cancer patients on systemic chemotherapy.. Journal of Clinical Oncology, 2017, 35, e12571-e12571.	1.6	2
104	Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen. Oral Oncology, 2021, 123, 105587.	1.5	2
105	Understanding hairy cell leukemia genetics. Leukemia and Lymphoma, 2007, 48, 653-654.	1.3	1
106	PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study. Annals of Oncology, 2016, 27, vi22.	1.2	1
107	P1.01-96 US Real-World Management of EGFR-Mutated Advanced NSCLC: Survival After First-Line EGFR-Tyrosine Kinase Inhibitor Treatment. Journal of Thoracic Oncology, 2019, 14, S398-S399.	1.1	1
108	Prognostic impact of XPO1 mutations in metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2021, 39, e20533-e20533.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Abstract 3619: The absence of cleaved caspase-3 in circulating tumor cells detected using a non-enrichment-based assay. , 2012, , .		1
110	Dynamic changes in circulating tumor cell levels as a prognostic marker in stage IV non-small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, 8109-8109.	1.6	1
111	Genetics of hairy cell leukemia. Oncology Reviews, 2008, 1, 189-194.	1.8	0
112	Convergent Science Physical Oncology. Convergent Science Physical Oncology, 2015, 1, 010201.	2.6	0
113	P2.06-011 Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC. Journal of Thoracic Oncology, 2017, 12, S1075-S1076.	1.1	0
114	Comparable Survival Between Upfront Tri-Modality Therapy and Definitive Chemoradiation Therapy Requiring Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e717.	0.8	0
115	MA21.01 Cbl Mutations (mt) as Important Mediators of Oncogenic RTK Signaling in NSCLC. Journal of Thoracic Oncology, 2018, 13, S429.	1.1	0
116	When it comes to genomic analysis of tumours, don't buy in bulk. British Journal of Cancer, 2018, 118, 1281-1282.	6.4	0
117	A phase 1 trial of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.. Journal of Clinical Oncology, 2021, 39, 3021-3021.	1.6	0
118	Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas.. Journal of Clinical Oncology, 2021, 39, e21000-e21000.	1.6	0
119	Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer. Journal of Investigative Medicine, 2021, 69, 1281-1286.	1.6	0
120	IMPACT OF EXPANDING LUNG CANCER SCREENING GUIDELINES ON THE EARLY DETECTION OF LUNG CANCER IN WOMEN AND MINORITIES. Chest, 2021, 160, A1611-A1612.	0.8	0
121	COVID-19 and the acceleration toward remote cancer care. Baylor University Medical Center Proceedings, 2022, 35, 259-260.	0.5	0
122	Patterns of Expression of SHP-1 and JAK-2p in Myelodysplastic Syndromes: A Potential New Prognostic Factor.. Blood, 2004, 104, 3430-3430.	1.4	0
123	Abstract 4151: High definition circulating tumor cells in patients with non-small cell lung cancer. , 2011, , .		0
124	Abstract 2369: Correlating circulating tumor cells with 18F-FDG positron emission tomography (PET) uptake in patients with treatment naïve non-small cell lung cancer: A pilot study. , 2012, , .		0
125	Correlation of ERCC1 expression on circulating tumor cells with progression-free survival in metastatic non-small cell lung cancer patients treated with platinum-based chemotherapy.. Journal of Clinical Oncology, 2012, 30, 10574-10574.	1.6	0
126	SU-EJ-115: Using Markov Chain Modeling to Elucidate Patterns in Breast Cancer Metastasis Over Time and Space. Medical Physics, 2014, 41, 182-182.	3.0	0

#	ARTICLE	IF	CITATIONS
127	A Markov chain model of a longitudinal breast cancer data set.. Journal of Clinical Oncology, 2014, 32, 11040-11040.	1.6	0
128	Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort.. Journal of Clinical Oncology, 2016, 34, 8524-8524.	1.6	0
129	Abstract 2711: Spatiotemporal progression patterns in metastatic lung cancer treated with bevacizumab. , 2016, , .		0
130	An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.. Journal of Clinical Oncology, 2017, 35, TPS6092-TPS6092.	1.6	0
131	Abstract 2603: A patient driven cancer database to collect information, analyze data, and predict outcomes. , 2017, , .		0
132	Abstract 4532: Adrenal metastases in lung cancer: Clinical implications of a mathematical model. , 2017, , .		0
133	Abstract 31: The INSPIRE trial: A randomized trial of neoadjuvant and adjuvant therapy with the IRX-2 regimen in patients with newly diagnosed stage II, III, or IVa squamous cell carcinoma of the oral cavity. , 2017, , .		0
134	Objective metrics of patient activity: Use of wearable trackers and patient reported outcomes in predicting unexpected healthcare events in cancer patients undergoing highly emetogenic chemotherapy.. Journal of Clinical Oncology, 2018, 36, 6519-6519.	1.6	0
135	Abstract 2963: Characterization of disease evolution in sequential sampled metastatic breast cancer using liquid biopsy. , 2018, , .		0
136	Abstract 4591: Integration of genomic analysis and assessment of pre-analytic variables in the HD-SCA workflow: A technical validation study. , 2018, , .		0
137	Abstract 4584: High-definition single-cell analysis of liquid and solid biopsies reveals heterogeneity of circulating tumor cells in metastatic colorectal cancer. , 2018, , .		0
138	KRAS-Mutated Lung Cancer. Current Cancer Research, 2019, , 195-216.	0.2	0
139	Abstract P3-01-09: Tracing clonal evolution of circulating tumor cells and cell-free DNA in a metastatic breast cancer patient. , 2019, , .		0
140	Tumor mutational burden (TMB) profile of <i>K-RAS/TP-53</i> co-mutation in metastatic non-small cell lung cancer (m-NSCLC).. Journal of Clinical Oncology, 2019, 37, 2626-2626.	1.6	0
141	Effect of mandatory research biopsy requirements on initiation of clinical trials.. Journal of Clinical Oncology, 2019, 37, e14057-e14057.	1.6	0
142	Gender disparities in hormone positive lung cancer.. Journal of Clinical Oncology, 2020, 38, e21552-e21552.	1.6	0
143	Is there a genomic fingerprint of Radon (Rn)-induced lung cancer (LC)? Comparison of genomic alterations in LC specimens from high and low Rn zones.. Journal of Clinical Oncology, 2020, 38, 1572-1572.	1.6	0
144	Abstract PL01-01: Physicist vs. physician: Digitizing clinical assessment and using it for evidence-based prediction of outcomes. , 2019, , .		0